They demonstrate that NRG4 derived from brown fat represses hepatic lipogenesis through the signaling of human epidermal growth factor receptor 3 (ErbB3, HER3) and ErbB4 (HER4), ultimately leading to the inhibition of nonalcoholic fatty liver disease (NAFLD) [105]. Here, ERBB3 is linked to metabolic dysfunction-associated steatotic liver disease.